International Reference Pricing in Medicare—Mismatch Between Policy and Evaluation
This Viewpoint explores whether savings from lower drug prices outweigh any downstream effects on manufacturer behavior, patient access, and future pharmaceutical innovation. from JAMA Health Forum New Online https://ift.tt/zuKIQbo